Wedbush Issues Negative Outlook for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at Wedbush lowered their Q3 2025 EPS estimates for shares of Nuvalent in a research note issued on Thursday, August 7th. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.31) per share for the quarter, down from their previous forecast of ($1.21). Wedbush currently has a “Outperform” rating and a $115.00 target price on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. Wedbush also issued estimates for Nuvalent’s Q4 2025 earnings at ($1.38) EPS, FY2026 earnings at ($6.17) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($1.78) EPS.

Several other equities analysts have also commented on the stock. Robert W. Baird upped their price objective on shares of Nuvalent from $105.00 to $112.00 and gave the stock an “outperform” rating in a report on Wednesday, June 25th. HC Wainwright restated a “buy” rating and issued a $130.00 price objective (up from $110.00) on shares of Nuvalent in a report on Tuesday, June 24th. Leerink Partners upped their price objective on shares of Nuvalent from $125.00 to $140.00 and gave the stock an “outperform” rating in a report on Tuesday, June 24th. Finally, The Goldman Sachs Group upgraded shares of Nuvalent to a “strong-buy” rating in a report on Monday, June 30th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $119.60.

Nuvalent Stock Performance

Shares of NUVL stock opened at $74.95 on Monday. The firm’s 50 day moving average price is $78.94 and its 200-day moving average price is $76.07. Nuvalent has a one year low of $55.53 and a one year high of $113.51. The firm has a market cap of $5.38 billion, a P/E ratio of -15.30 and a beta of 1.30.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.04). During the same quarter last year, the firm earned ($0.88) EPS.

Institutional Investors Weigh In On Nuvalent

Large investors have recently modified their holdings of the company. CWM LLC increased its position in shares of Nuvalent by 588.5% in the 1st quarter. CWM LLC now owns 420 shares of the company’s stock valued at $30,000 after purchasing an additional 359 shares during the last quarter. Quarry LP purchased a new stake in shares of Nuvalent in the 4th quarter valued at approximately $39,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Nuvalent in the 1st quarter valued at approximately $38,000. Covestor Ltd increased its position in shares of Nuvalent by 705.7% in the 1st quarter. Covestor Ltd now owns 983 shares of the company’s stock valued at $70,000 after purchasing an additional 861 shares during the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Nuvalent in the 2nd quarter valued at approximately $88,000. 97.26% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Nuvalent news, insider Henry E. Pelish sold 5,500 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $74.85, for a total transaction of $411,675.00. Following the sale, the insider directly owned 60,956 shares in the company, valued at $4,562,556.60. This represents a 8.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Alexandra Balcom sold 14,700 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $85.10, for a total transaction of $1,250,970.00. Following the sale, the chief financial officer owned 61,734 shares in the company, valued at approximately $5,253,563.40. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,145 shares of company stock worth $7,419,532 in the last ninety days. 10.20% of the stock is owned by corporate insiders.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.